<DOC>
	<DOCNO>NCT00043719</DOCNO>
	<brief_summary>Osteopenia osteoporosis cause thin bone tissue loss bone density time . The purpose study determine safety effectiveness nitroglycerin ointment treatment osteopenia postmenopausal woman . Study hypothesis : On average , participant base therapy cohort receive placebo ointment control calcium/vitamin D lose bone density participant nitroglycerin cohort 36-month period .</brief_summary>
	<brief_title>Nitroglycerin Ointment Preventing Bone Loss Postmenopausal Women</brief_title>
	<detailed_description>Imbalance activity osteoclast ( cell responsible bone loss ) osteoblasts ( cell responsible bone formation ) may lead fracture , osteopenia , osteoporosis postmenopausal woman . During postmenopause , decrease estrogen level decrease nitric oxide production occur ; estrogen replacement therapy show restore serum nitric oxide level normal . Reversing nitric oxide deficiency use nitroglycerin may prevent bone loss . The Nitroglycerin Option : Value Early Bone Loss ( NOVEL ) study test safety efficacy nitroglycerin ointment treatment osteopenia postmenopausal woman . Patients enrol study 3 year randomly assign one two group . The first group receive nitroglycerin ointment , second group receive placebo ointment . All patient give calcium supplement vitamin D take daily , instruct rub give ointment skin daily . Study visit occur Month 2 every six month Month 2 . Phone interview conduct patient every 2 month throughout study .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Nitroglycerin</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>Postmenopausal minimum 13 month Lumbar spine Tscore 0 2.5 ( 0 2.0 60 year old ) Dual Energy Xray Absorptiometry ( DEXA ) ( i.e. , evidence normal bone mass osteopenia ) Body Mass Index ( BMI ) 18 32 Planning live great New Brunswick , NJ , area least 3 year Radiographically DEXAmorphometrically proven vertebral hip fracture Conditions require routine use sublingual , transdermal , oral nitrate Significant postmenopausal symptom require estrogen therapy Metabolic bone diseases postmenopausal bone loss ( e.g. , active hyperthyroidism , hyperparathyroidism , Paget 's disease bone , etc . ) Insulindependent diabetes mellitus Significant migraine headache History renal calculus Cancer within 5 year prior study entry Any condition causing anticipated life expectancy le 3 year Failure maintain 75 % 125 % compliance openlabel calcium vitamin D regimen screen period</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Human Female</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Nitric Oxide</keyword>
	<keyword>Nitroglycerin</keyword>
	<keyword>Calcium</keyword>
	<keyword>Vitamin D</keyword>
</DOC>